6-methoxy-4-(piperazin-1-yl)-7-(3-(piperidin-1-yl)propoxy)quinazoline | 461429-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-methoxy-4-(piperazin-1-yl)-7-(3-(piperidin-1-yl)propoxy)quinazoline
• 英文别名: 6-Methoxy-4-piperazin-1-yl-7-(3-piperidin-1-ylpropoxy)quinazoline
• CAS: 461429-53-8
• 化学式: C₂₁H₃₁N₅O₂
• 分子量: 385.509
• InChiKey: POFYXPVWTYBPPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-氰基苯异氰酸酯 、 6-methoxy-4-(piperazin-1-yl)-7-(3-(piperidin-1-yl)propoxy)quinazoline 以 N,N-二甲基甲酰胺 为溶剂， 以0.025 g的产率得到N-(4-cyanophenyl)-4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]piperazine-1-carboxamide
  参考文献：
  名称：

  Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family

  摘要：

  We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation. A series of highly potent, specific, orally active, small molecule kinase inhibitors directed against members of PDGFR receptor have been developed through modifications of the novel quinazoline template I. Systematic modifications in the A-bicyclic ring and D-rings of protype I were carried out to afford potent analogues, which display IC50 values of <250 nM in cellular betaPDGFR phosphorylation assays. An optimized analogue in this series, 75 (CT53518), inhibits Flt-3, betaPDGFR, and c-Kit receptor phosphorylation with IC50 values of 50-200 nM, whereas 15-20-fold less potent activity against CSF-1R was observed. This analogue also inhibits autophosphorylation of Flt-3 ligand-stimulated wild-type Flt-3 and a constitutively activated Flt-3/internal tandem duplication (ITD) with IC50 values of 30-100 nM. Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T-1/2 > 8 h). Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia.

  DOI：

  10.1021/jm020143r
• 作为产物：
  描述：

  香草酸 在 palladium dihydroxide 盐酸 、 氯化亚砜 、 氢气 、 硝酸 、 甲酸铵 、 potassium carbonate 、 caesium carbonate 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 、 tin(ll) chloride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 20.0~150.0 ℃ 、344.74 kPa 条件下， 反应 9.0h， 生成 6-methoxy-4-(piperazin-1-yl)-7-(3-(piperidin-1-yl)propoxy)quinazoline
  参考文献：
  名称：

  Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family

  摘要：

  We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation. A series of highly potent, specific, orally active, small molecule kinase inhibitors directed against members of PDGFR receptor have been developed through modifications of the novel quinazoline template I. Systematic modifications in the A-bicyclic ring and D-rings of protype I were carried out to afford potent analogues, which display IC50 values of <250 nM in cellular betaPDGFR phosphorylation assays. An optimized analogue in this series, 75 (CT53518), inhibits Flt-3, betaPDGFR, and c-Kit receptor phosphorylation with IC50 values of 50-200 nM, whereas 15-20-fold less potent activity against CSF-1R was observed. This analogue also inhibits autophosphorylation of Flt-3 ligand-stimulated wild-type Flt-3 and a constitutively activated Flt-3/internal tandem duplication (ITD) with IC50 values of 30-100 nM. Through this optimization process, 75 was found to be metabolically stable and has desirable pharmacokinetic properties in all animal species studied (F% > 50%, T-1/2 > 8 h). Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia.

  DOI：

  10.1021/jm020143r

文献信息

• Synthesis and antitumor activity evaluation of quinazoline derivatives bearing piperazine-1-carbodithioate moiety at C4-position
  作者：Ying Zhang、Chao-Rui Yang、Xue Tang、Sheng-Li Cao、Ting-Ting Ren、Man Gao、Ji Liao、Xingzhi Xu

  DOI：10.1016/j.bmcl.2016.08.060

  日期：2016.10

  A series of quinazoline derivatives bearing piperazine-1-carbodithioate moiety at the C4-position were synthesized using piperidine and 1-bromo-3-chloropropane as starting materials via eight steps. Final compounds 8a-q and 9a-i were evaluated for their antiproliferative activity against human lung cancer A549, breast adenocarcinoma MCF-7, and colorectal cancer HCT-116 cell lines. The results showed

  以哌啶和1-溴-3-氯丙烷为原料，经八个步骤合成了一系列在C4位带有哌嗪-1-碳二硫代酸酯部分的喹唑啉衍生物。评估了最终化合物8a-q和9a-i对人肺癌A549，乳腺癌MCF-7和结肠直肠癌HCT-116细胞系的抗增殖活性。结果表明，在26种最终化合物中，有14种抑制了三种癌细胞系的增殖，IC50值均小于10μM。当用代表性化合物8n处理时，HCT-116细胞停滞在细胞周期的G0 / G1期。这为进一步研究作用机理提供了线索。
• [EN] NOVEL FUSION MOLECULES AND USES THEREOF<br/>[FR] NOUVELLES MOLÉCULES DE FUSION ET LEURS UTILISATIONS
  申请人：FOUNDATION MEDICINE INC

  公开号：WO2014071419A2

  公开（公告）日：2014-05-08

  Novel fusion molecules and uses are disclosed.